DNAJC5 and malaria: In particular, analysis of polymorphic sites and haplotypes within the CSP gene in samples from an RTS,S/AS01 vaccine trial found that the 1-year cumulative vaccine efficacy was 50.3% against clinical malaria with parasites matching the vaccine sequence in the entire CSP C-terminal, as compared with an efficacy of 33.4% against those with mismatching sequences [116].